title: [Adverse effects of new biological therapies for non-small-cell bronchial cancer].
abstract: Biological therapies targeted at bronchial cancer have a mode of action different from that of the various types of chemotherapies and are therefore associated with different types of toxicity. EGFR inhibitors cause mainly cutaneous toxicity, which can be controlled by cyclin and local care. Antiangiogenic agents increase the risk of arterial thrombosis and the risk of minor (nosebleeds) or severe (hemoptysis) bleeding. Hypertension is also a frequent side effect, generally controlled by standard antihypertensive treatment, preferably calcium channel blockers or angiotensin-converting enzyme inhibitors. Combined management by an oncologist, specialists in the relevant organs (lungs, heart, and skin) and a general practitioner is essential for optimal management of these frequent but rarely severe drug events.
authors.affiliation: Université de Toulouse III (Paul Sabatier), faculté de médecine, CHU de Toulouse, institut des maladies métaboliques et cardiovasculaires, fédération des services de cardiologie, service de pharmacologie clinique, Inserm U1048, 31000 Toulouse, France.
authors.forename: Marion
authors.initials: M
authors.lastname: Castel
authors.forename: Atul
authors.initials: A
authors.lastname: Pathak
authors.forename: Fabien
authors.initials: F
authors.lastname: Despas
authors.forename: Julien
authors.initials: J
authors.lastname: Mazières
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003299:Cooperative Behavior; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D033183:Interdisciplinary Communication; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010348:Patient Care Team; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D001688:Biological Products; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib